Home Compare GILD vs GSK.L
Stock Comparison · Industry comparison · Drug Manufacturers - General

Gilead Sciences vs GSK: Which Stock Looks Stronger in 2026?

The structural profiles are close, with Gilead Sciences carrying a narrow edge on profitability. GSK still has the edge on growth, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Profitability is the clearest driver, while growth keeps the result from looking one-way.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. GILD and GSK.L share the same industry classification.

For a similarity-based comparison, see how Gilead Sciences and GSK each position within their functional peer groups in AssetNext.

Peer-Relative Score
GILD
Gilead Sciences, Inc.
70
Peer-Score
Signal qualityHigh
vs
GSK.L
GSK plc
65
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The clearest separation appears in profitability.

Dimension spread: GILD vs GSK.L Profitability 79 46 Stability 65 69 Valuation 83 80 Growth 44 71 GILD GSK.L
Gap Ranking
#1 Profitability +33
#2 Growth +27
#3 Stability +4
#4 Valuation +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GILD and GSK.L Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GILDGSK.L Relative valuation Structural strength

The structural gap is limited here, but current pricing still leans against GSK plc.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
Both profiles are strong on profitability, but Gilead Sciences, Inc. leads clearly.
Growth
On growth, the edge is clear — both rank well, but GSK plc sits noticeably higher.
Profitability — Dominant Gap
GILD
79
GSK.L
46
Gap+33in favour of GILD

The profitability lead is mainly driven by a 18.4-point operating margin advantage.

What keeps the gap from being one-sided

Earnings growth also leans the other way, which keeps the score lead from reading as a full growth sweep.

What this means for the comparison

The main read on profitability is clearer than the broader score gap.

Explore full peer positioning in AssetNext

Break down the GILD vs GSK.L comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how GILD and GSK.L each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.